Horizon Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Horizon Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 
DEERFIELD, IL -- (Marketwired) -- 12/05/13 --   Horizon Pharma, Inc.
(NASDAQ: HZNP) today announced that on December 4, 2013 the
Compensation Committee of its Board of Directors approved the grant
of inducement stock options to purchase an aggregate of 80,250 shares
of common stock to 14 new employees. 
Each stock option has an exercise price per share equal to $6.93, the
fair market value on the grant date, and vests over four years, with
25% of the shares vesting on the one-year anniversary of the
applicable vesting commencement date and 1/48 of the shares vesting
monthly thereafter, subject to the new employee's continued service
relationship with the Company. Each stock option also has a ten year
term and is subject to the terms and conditions of the Company's 2011
Equity Incentive Plan and the stock option agreement pursuant to
which the option was granted. 
The stock options were granted as inducements material to the new
employees entering into employment with Horizon Pharma in accordance
with NASDAQ Listing Rule 5635(c)(4). 
About Horizon Pharma 
Horizon Pharma, Inc. is a specialty pharmaceutical company that has
developed and is commercializing products to primary care, orthopedic
surgeons, and rheumatologists. The Company markets DUEXIS, and
RAYOS/LODOTRA, and will market VIMOVO, which target unmet therapeutic
needs in arthritis, pain and inflammatory diseases. The Company's
strategy is to develop, acquire and/or in-license additional
innovative medicines where it can execute a targeted commercial
approach among specific target physicians while taking advantage of
its commercial strengths and the infrastructure the Company has put
in place. For more information, please visit www.horizonpharma.com. 
Robert J. De Vaere
Executive Vice President and Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.